Chenyu Lin, MD
Hematology & Oncology · Durham, NCNPI 1093177545
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,050 of the $13,515 with a category attached, or 67.0%. ADC Therapeutics America, Inc. accounts for 70.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $9,676 and has fallen 67.8% since, to $3,121 in 2025.
Across 21 payments — averaging $643.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$10K
- Autolus Inc$2K
- Daiichi Sankyo Inc.$650
- AbbVie$207
- Jazz Pharmaceuticals Inc.$147
- Johnson & Johnson$125
- plus $364 from 4 others
Across 1 payment — averaging $26,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$27K
What the payments were for
- Consulting fees$9,05067%
- Speaking & faculty fees$2,34017%
- Travel & lodging$8426%
- Food & beverage$1,2009%
- Education$831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 10 | $9,551 |
| Autolus Inc | 2 | $2,471 |
| Daiichi Sankyo Inc. | 1 | $650 |
| AbbVie | 2 | $207 |
| Jazz Pharmaceuticals Inc. | 1 | $147 |
| Johnson & Johnson | 1 | $125 |
| Gilead | 1 | $125 |
| Incyte Corporation | 1 | $113 |
| Beigene USA, Inc. | 1 | $86 |
| Rigel Pharmaceuticals, Inc. | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,515 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 59 | $688 |
| Prochlorperazine Maleate | 12 | $130 |
| Prednisone | 32 | $88 |
| Ondansetron Hcl | 11 | $69 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Durham
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Matthew McKinneyDurham$277K
- Taewoong ChoiDurham$207K
- Ivy AltomareDurham$164K
- Jeffrey CrawfordDurham$125K
- Carlos de CastroDurham$124K
- Joseph MooreDurham$97K
- Ammon FagerDurham$56K
- Jameel MuzaffarDurham$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.